Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial | Zendy

Peter Daley | Zendy; Thomas Louie | Zendy; J E Lutz | Zendy; Sahil Khanna | Zendy; Uschi Stoutenburgh | Zendy; Man Jin | Zendy; Adedayo Adedoyin | Zendy; Laurent Chesnel | Zendy; Dalya Güriş | Zendy; Kajal Larson | Zendy; Yoshihiko Murata | Zendy

Open Access

Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial

Author(s) -

Peter Daley,

Thomas Louie,

J E Lutz,

Sahil Khanna,

Uschi Stoutenburgh,

Man Jin,

Adedayo Adedoyin,

Laurent Chesnel,

Dalya Güriş,

Kajal Larson,

Yoshihiko Murata

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx299

Subject(s) - vancomycin , medicine , clostridium difficile , placebo , clinical trial , randomized controlled trial , surgery , antibiotics , staphylococcus aureus , microbiology and biotechnology , alternative medicine , pathology , biology , bacteria , genetics

The available treatment options for Clostridium difficile infection (CDI) are limited by high recurrence rates. Surotomycin was a novel bactericidal cyclic lipopeptide in development to treat CDI that demonstrated non-inferiority to vancomycin in a Phase 2 trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research